Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine.
Heather MillerJohan Karlsson WallmanIngemar F PeterssonSaedis SaevarsdottirJonas SöderlingSofia ErnestamJohan AsklingRonald van VollenhovenMartin NeoviusPublished in: Rheumatology (Oxford, England) (2021)
clinicaltrials.gov, identifier: NCT00764725.